EAU 2013 - Programme Book - YouMed

Monday
704 Tumour recurrence and intravesical BCG significantly impact upon health related quality of life in patients
undergoing conservative management for superficial bladder cancer
N. Sapre, A. Wooten, H. Siddons, A.J. Costello, C.M. Hovens, N.M. Corcoran, P. Anderson (Melbourne,
Australia)
705 BCG induced bladder and systemic adverse events assessed by weekly self-administered questionnaire
can predict SAEs and course interruption
B. Tamarelle, A. Picard, N. Arfi, A. Pages, X. Martin, M. Colombel (Lyon, France)
706 Early vs delayed mitomycin C instillations after TUR in patients with non-muscle invasive bladder tumours:
A prospective multicentre randomised trial
T. Van Ginkel, J. Nieuwenhuijzen, R. Ter Haar, D. Newling, R.J.A. Van Moorselaar (Amsterdam, The
Netherlands)
707 Organ preservation in high- and extreme high risk non-muscle-invasive bladder cancer (NMIBC): Outcome
analysis of an interventional cohort study of the German Hyperthermia Chemotherapy Group in efficacy
and side effects
G.C. Lüdecke, L. Schäfer, W. Weidner, F. Hasner, H. Hanitzsch, M. Schmidt (Giessen, Munich, Bonn,
Germany)
* 708 Side effects of BCG in the treatment of intermediate and high risk Ta T1 papillary carcinoma of the bladder:
Results from EORTC GU Cancers Group randomized study 30962 comparing 1/3 dose vs full dose during 1
or 3 years
M. Brausi, J. Oddens, R. Sylvester, S. Colette, P. Gontero, A. Bono, L. Turkeri (Modena, Turin, Varese, Italy;
Hertogenbosh, The Netherlands; Brussels, Belgium; Istanbul, Turkey)
240 Programme Book
Discussion on poster 708
M. Rouprêt, Paris (FR)